BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: **MRIDULA A GEORGE**

eRA COMMONS USER NAME (credential, e.g., agency login): mridula

POSITION TITLE: Assistant Professor of Medicine

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY
Rutgers University	B. S	01/2007	Chemistry
Rutgers- Robert Wood Johnson Medical School	M.D	05/2012	Medicine
University of Massachusetts	Residency	06/2015	Internal Medicine
Rutgers- Robert Wood Johnson Medical School	Fellowship	06/2018	Hematology & Oncology

A. Personal Statement

I am an Assistant Professor of Medicine at Rutgers Robert Wood Johnson Medical School. My clinical practice is primarily focused on the management of early and advanced breast cancer in the Stacy Goldstein Breast Cancer Center. As one of the nation's NCI-designated comprehensive cancer centers and the only one in New Jersey, the cancer center is a high-volume referral center for advanced complex cases.

As an oncologist at an academic institution, I have a career interest to lead clinical research, collaborate with colleagues engaged in cancer research, and educate and mentor trainees interested in oncology. Most relevant to this research, I have experience in collaborating on studies that evaluate the use and outcomes of cancer therapies among real-world patients. I am principal investigator on multiple investigator-initiated clinical trials. I have an ongoing clinical trial that evaluates the combination of oncolytic virus pelareorep with PD-1 inhibitor retifanlimab in patients with metastatic triple negative breast cancer. I have other studies that evaluates the role of circulating tumor DNA (ctDNA) in patients with Stage II and Stage III breast cancer and the potential of ctDNA to guide treatment decision making in the adjuvant setting. In addition to my clinical practice, I perform clinical research, and educate and mentor hematology/oncology fellows, internal medicine residents and medical students.

B. Positions, Scientific Appointments, and Honors

POSITIONS

6/2008-8/2008	NIH Summer Student Research Fellowship, National Institute of Health, Bethesda, MD
2012-2013	Intern, Internal Medicine, University of Massachusetts Medical School, Worcester, MA
2013-2015	Resident, Internal Medicine, University of Massachusetts Medical School, Worcester, MA
2015-2018	Fellow, Hematology & Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
2018-Present	Assistant Professor, Department of Medicine, Cancer Institute of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ

SCIENTIFIC POSITIONS

2018-Present	Breast Clinical Trial Working Group, Big Ten Cancer Research Consortium
2019-2020	American Society of Clinical Oncology (ASCO) Virtual Mentoring Program, Mentor: Dr. Jennifer Gao.
2019 - Present	Member, Human Research Oversight Committee (DSMB), Rutgers Cancer Institute of New Jersey
2019	American Society of Clinical Oncology (ASCO) Educational Book Expert Panel
2019	34th Annual Meeting Abstract Review Committee, Society for Immunotherapy of Cancer (SITC)
2019 – Present	Member, Clinical Investigations and Precision Therapeutics Program, Rutgers Cancer Institute of NJ
2020 to present	Rutgers Cancer Institute, Immune Monitoring and Advanced Genomics Shared Resource, Member
2022 to present	Rutgers Robert Wood Johnson Medical School- Hematology/Oncology Fellowship, Core Faculty

HONORS

2003-2007	Rutgers University- Dean's list
8/2004	Rutgers–New Jersey Medical School Poster presentation award, Summer Students Research Program.
1/2007	Rutgers University Magna cum laude
6/2008-8/2008	Summer Student Research Fellowship, National Institute of Health, Bethesda, MD
5/2012	Rutgers Robert Wood Johnson Medical School - Distinction in Service to the Community,
9/2017	FDA/ASCO Research Workshop, Bethesda MD
6/2019	AACR/ESMO/EORTC Methods in Clinical Cancer Research, Zeist, Netherlands
9/2021-12/2021	OASIS Leadership and Professional Development Program
8/2022	NCI- Annual Early Career Investigator Letter of Intent Writing Workshop
6/2022-12/2022	North America Star Consortium and the Johns Hopkins LAO- ARTES Leadership Course (ongoing)

C. Contributions to Science

1. Utilization and effectiveness of cancer therapies among patients with breast cancer. I am interested in the real-world use and outcomes of cancer treatments. As a practicing oncologist, I recognize clinical judgment, patient preference, and health system resources impact the use and effectiveness of therapies. It is important to evaluate how therapies are used and potential benefits and risks of these therapies among patients outside of clinical trials.

Sayan M, Vergalasova I, **George M**, Kowzun M, Potdevin L, Kumar S, Haffty B, Ohri N. Patterns of postmastectomy radiation therapy in clinically node-positive breast cancer patients with pathologically negative lymph nodes after neoadjuvant chemotherapy. Turk J Med Sci. 2022 Apr;52(2):279-285. doi: 10.55730/1300-0144.5313. Epub 2022 Apr 14.

George MA, Qureshi S, Omene C, Toppmeyer DL, Ganesan S. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer. Front Oncol. 2021 Jul 12;11:693104. doi: 10.3389/fonc.2021.693104. PMID: 34327137; PMCID: PMC8313476.

Sayan M, Vergalasova I, Jhawar S, Kumar S, **George M**, Kowzun M, Potdevin L, Toppmeyer D, Haffty B, Ohri N. Utilization of Hypofractionated Whole-Breast Radiotherapy With Concurrent Anti-Human Epidermal Growth Factor Receptor 2 (HER2) Therapy. Clin Breast Cancer. 2021 Feb;21(1):31-36. doi: 10.1016/j.clbc.2020.06.007. Epub 2020 Jun 29.

2. Study Oncolytic viruses with Checkpoint inhibitors: I am the Principal investigator on an investigator initiated clinical trial studying the combination of Pelareorep with checkpoint inhibitor in metastatic triple

negative breast. I am also the site PI of a Pre-COG study evaluating the combination of pelareorep, taxane based chemotherapy and checkpoint inhibitor in metastatic hormone receptor positive breast cancer. Both studies are currently accruing patients.

Mridula George, Nicole Williams, Maryam Lustberg, Coral Omene, Nancy Chan, Nisha Ohri, Maria Kowzun, Li ndsay Potdevin, Firas Eladoumikdachi, Shicha Kumar, Robert Wesolowski, Grey Wilkinson, Danielle Tang, Sin ae Kim, Shridar Ganesan, Bruce Haffty and Deborah Toppmeyer. Cancer Res February 15 2021 (81) (4 Supplement) OT-32-02.

3. Evaluating the role of circulating tumor DNA (ctDNA): I recently received a pilot award from Natera to study the role of ctDNA in patients with triple negative and HER2 positive breast cancer. The study protocol is currently under institutional review. I am also collaborating with two other senior oncologists at Rutgers Cancer Institute of New Jersey to evaluate the potential to leverage circulating tumor DNA in early-stage hormone receptor positive breast cancer as part of treatment paradigm. We aim to extend study enrollment among the Big Ten clinical research consortium to evaluate the effectiveness of CDK4/6 inhibitor in patients with detectable ctDNA.

Qureshi S, Chan N, **George MA**, Ganesan S, Toppmeyer D, Omene C. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker. Biomark Insights. 2022 Feb 22;17:11772719221078774.

4. **Leadership in breast cancer clinical trials**: I am a site Principal Investigator of multiple cooperative group and industry clinical trials.

Chan N, Riedlinger GM, Lu Se, Pham KT, Kirstein LJ, Eladoumikdachi FE, **George MA**, Potdevin LB, Kowzun MJ, Desai SA, Tang DM, Omene CO, Wong ST, Rodriguez-Rust L, Kumar S, Kearney TJ, Liu C, Ganesan S, Toppmeyer DL, Hirshfield KM. Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of triple negative breast cancer. CANCER RESEARCH, 2019, 79 (4 Supplement).

Nancy Chan, Dirk Moore, Pavankumar Tandra, Jatin Rana, Coral Omene, **Mridula George**, et al. (2022) Abstract OT1-17-02 "A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients. 2021 San Antonio Breast Cancer Symposium®, December 7-10, 2021

George MA, Mayer TM, Moore D, Chen C, White E, DiPaola RS, Chandrika Jeyamohan, Mark N. Stein. Autophagic cell death with hydroxychloroquine in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. (2017) J*ournal of Clinical Oncology* 35;6 suppl 102-102. [Presented at GU ASCO 2017]

List of Published Work in MyBibliography:

https://www.ncbi.nlm.nih.gov/myncbi/1DonjjXKe-fc-g/bibliography/public/